2,8,9,13B-TETRAHYDRO-6-H-ISOQUINO-[2.1-B]-PYRROLO-[4.3.2-DE]-ISOQUINOLINO
Compound with spectra: 1 NMR
![2,8,9,13B-TETRAHYDRO-6-H-ISOQUINO-[2.1-B]-PYRROLO-[4.3.2-DE]-ISOQUINOLINO](/api/compound/Gfgv8kadbyM.png?ph=true&h=300&w=458 "2,8,9,13B-TETRAHYDRO-6-H-ISOQUINO-[2.1-B]-PYRROLO-[4.3.2-DE]-ISOQUINOLINO")
| SpectraBase Compound ID | Gfgv8kadbyM |
|---|---|
| InChI | InChI=1S/C18H16N2/c1-2-6-14-12(4-1)8-9-20-11-13-5-3-7-16-17(13)15(10-19-16)18(14)20/h1-7,10,18-19H,8-9,11H2 |
| InChIKey | VAGUGVHWYBXLRK-UHFFFAOYSA-N |
| Mol Weight | 260.34 g/mol |
| Molecular Formula | C18H16N2 |
| Exact Mass | 260.131349 g/mol |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | DMSO-D6 |
2-(4-fluorophenyl)-1-(1-methyl-1H-indol-3-yl)-1,2,3,4-tetrahydroisoquinoline
7H-Benz[de]isoindolo[1,2-a]isoquinolin-9(13bH)-one, (.+-.)-
1-(1H-indol-3-yl)-2-(phenylsulfonyl)-1,2-dihydroisoquinoline
2-Acetyl-1-(4-chloro-phenyl)-1,2,3,5-tetrahydro-pyridazino[4,5-b]indol-4-one
Methyl 5-acetyl-6-(2-methyl-1-propenyl)-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indole-4-carboxylate
3,3,7,8-tetramethyl-11-(2-thienyl)-2,3,4,5,10,11-hexahydro-1H-dibenzo[b,e][1,4]diazepin-1-one
#18-Z;METHYL-4,6-O-BENZYLIDENE-2-DEOXY-2-[(1Z)-2,5-(BENZYLIMINO)-1,2,5-TRIDEOXY-3,4-O-ISOPROPYLIDENE-L-RIBITOL-1C-YLIDENE]-ALPHA-D-ARABINO-HEXOPYRANOSID
#18-E;METHYL-4,6-O-BENZYLIDENE-2-DEOXY-2-[(1E)-2,5-(BENZYLIMINO)-1,2,5-TRIDEOXY-3,4-O-ISOPROPYLIDENE-L-RIBITOL-1C-YLIDENE]-ALPHA-D-ARABINO-HEXOPYRANOSID
5-Methoxy-4-methyl-8-(4-phenoxybutoxy)psoralen
4-(2-methoxyphenyl)-1-methyl-3-pentyl-2,6-diphenyl-4-piperidinol
| Title | Journal or Book | Year |
|---|---|---|
| Dopamine Receptor Ligands. Part 18: Modification of the Structural Skeleton of Indolobenzazecine-Type Dopamine Receptor Antagonists | Journal of Medicinal Chemistry | 2010 |